Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 44

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 44
---
) failure to declare or pay any dividend when due; (iii) the failure to timely file or make effective a registration statement on Form S-1 or Form S-3 pursuant to the Registration Rights Agreement (as defined below), (iv) the Company’s failure to cure a conversion failure or notice of the Company’s intention not to comply with a request for conversion of any Series D Preferred Stock, and (iv) bankruptcy or insolvency of the Company.

<div align='center'>19</div>

Other Adjustments.In
connection with the April 2025 Private Placement, the Company has agreed to seek stockholder approval at a special meeting of stockholders,
of the issuance of Conversion Shares at a conversion price below the Conversion Price (the date of such approval, the “Series D
Stockholder Approval Date”). If the Company did not obtain such stockholder approval prior to May 31, 2025, then the Company
would have been required to (i) file a preliminary Proxy Statement seeking such stockholder consent with the SEC no later than May 31,
2025, (ii) use reasonable best efforts to file the definitive Proxy Statement no later than June 30, 2025 and (iii) use
reasonable best efforts to hold the Stockholder Meeting no later than July 31, 2025. Such stockholder approval was obtained on May
29, 2025. If, on or after the Series D Stockholder Approval Date, the Company issues any shares of Common Stock for a consideration
per share (the “New Issuance Price”) less than a price equal to the Series D Conversion Price in effect immediately
prior to such issuance, the Conversion Price shall be reduced to the Series D New Issuance Price.

If 30 days
or 60 days following the occurrence of the later of (x) the Series D Stockholder Approval Date and (y) the earlier
of (a) the effective date of the registration statement to be filed pursuant to the Registration Rights Agreement and (b) the
date that the Series D Preferred Stock is eligible to be resold without restriction under Rule 144 of the Securities Act, the
Series D Conversion Price then in effect is the greater of $3.12 and the Market Price (as defined in the Series D Certificate
of Designations) then in effect (the “Series D Adjustment Price”), the Conversion Price shall automatically lower to
the Series D Adjustment Price.

On August 13, 2025, the Company
and the Investors